Taken together, these data indicate that STAT3-targeting, especially in myeloid cells, is effective in tempering CRS-associated immunopathological disorders triggered by the accumulation of FLIP-expressing cells. The gene discussed is CFLAR; the disease is congenital rubella syndrome.